Emergent BioSolutions

Hope replaces hype for coronavirus stocks

Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.

October 03, 2018

Few biopharma buyouts in quiet third quarter

The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.

August 31, 2018

Working for the government proves extremely profitable for Emergent

With its latest acquisition Emergent Biosolutions is tapping into new ways to access public spending.

September 16, 2015

For some elderly drugs resuscitation is the right medicine

June 25, 2013

Therapeutic focus – The tide turns slowly in chronic lymphocytic leukaemia

January 03, 2013

Deals over the Christmas period

January 03, 2012

Alliances over the Christmas period

August 11, 2011

Vantage Point - Biotech partners force shifts in US biosecurity funding

August 13, 2010

Emergent seeks diversity in Trubion purchase

July 03, 2009

Generics still doing well amongst small-caps in first half

April 17, 2009

Emergent shareholders lose faith on contract delay

Load More